REG - Diaceutics PLC - Purchase of Shares and PDMR Shareholding

Stifel FinancialAnnouncement

05/10/2022 09:33

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221005:nRSE7914Ba&default-theme=true

RNS Number : 7914B  Diaceutics PLC  05 October 2022

 

5 October 2022

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

Purchase of Shares and PDMR Shareholding

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
diagnostic commercialisation company which provides data, analytics and
technology enabled services via its proprietary DXRX platform to the precision
medicine market, announces that on 4 October 2022, Deborah Davis, the Chair of
Diaceutics, purchased 21,200 ordinary shares of £0.002 each in the Company
("Ordinary Shares") at a price of 81 pence per Ordinary Share. As a result of
the purchase, Deborah's shareholding is 86,000 Ordinary Shares, representing
approximately 0.10% of the Company's issued share capital.

 

 

Enquiries:

 Diaceutics PLC
 Nick Roberts, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

Diaceutics' data capability is one of the three key value drivers it has
integrated into its unique DXRX platform alongside its global Lab network and
product suite tailored for Precision testing.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Deborah Davis
 2   Reason for notification
 a.  Position/Status                                              Chair
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Purchase
 c.  Price(s) and volume(s)                                                    Share purchase:
                                                                               Price(s)     Volume(s)
     81 p                                                                      21,200

 d.  Date of the transaction                                      4 October 2022
 e.  Place of the transaction                                     AIM Market of the London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFFLISLSIIF